Therapeutic compounds targeting Lipid II for antibacterial purposes

References

• Breukink E, de Kruijff B. Lipid II as a target for antibiotics. Nat Rev Drug Discov. 2006;5(4):321–332. doi:10.1038/nrd200416531990
   PubMed Web of Science ®Google Scholar
• van Heijenoort J. Lipid intermediates in the biosynthesis of bacterial peptidoglycan. Microbiol Mol Biol Rev. 2007;71(4):620–635. doi:10.1128/MMBR.00016-0718063720
   PubMed Web of Science ®Google Scholar
• de Kruijff B, van Dam V, Breukink E. Lipid II: a central component in bacterial cell wall synthesis and a target for antibiotics. Prostaglandins Leukot Essent Fatty Acids. 2008;79(3–5):117–121. doi:10.1016/j.plefa.2008.09.02019008088
   PubMed Web of Science ®Google Scholar
• Hsu ST, Breukink E, Tischenko E, et al. The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat Struct Mol Biol. 2004;11(10):963–967. doi:10.1038/nsmb83015361862
   PubMed Web of Science ®Google Scholar
• Okesola AO. Community-acquired methicillin-resistant Staphylococcus aureus–a review of literature. Afr J Med Med Sci. 2011;40(2):97–107.22195376
   PubMedGoogle Scholar
• Bolla JR, Sauer JB, Wu D, et al. Direct observation of the influence of cardiolipin and antibiotics on lipid II binding to MurJ. Nat Chem. 2018;10(3):363–371. doi:10.1038/nchem.291929461535
   PubMed Web of Science ®Google Scholar
• Ruiz N. Lipid Flippases for Bacterial Peptidoglycan Biosynthesis. Lipid Insights. 2015;8(Suppl 1):21–31. doi:10.4137/LPI.S3178326792999
   PubMedGoogle Scholar
• Mohammadi T, van Dam V, Sijbrandi R, et al. Identification of FtsW as a transporter of lipid-linked cell wall precursors across the membrane. EMBO J. 2011;30(8):1425–1432. doi:10.1038/emboj.2011.6121386816
   PubMed Web of Science ®Google Scholar
• Zapun A, Noirclerc-Savoye M, Helassa N, Vernet T. Peptidoglycan assembly machines: the biochemical evidence. Microb Drug Resist. 2012;18(3):256–260. doi:10.1089/mdr.2011.023622432702
   PubMed Web of Science ®Google Scholar
• Ganchev DN, Hasper HE, Breukink E, de Kruijff B. Size and orientation of the lipid II headgroup as revealed by AFM imaging. Biochemistry. 2006;45(19):6195–6202. doi:10.1021/bi051913e16681392
   PubMed Web of Science ®Google Scholar
• Hasper HE, Kramer NE, Smith JL, et al. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. Science. 2006;313(5793):1636–1637. doi:10.1126/science.112981816973881
   PubMed Web of Science ®Google Scholar
• Bugg TD, Brandish PE. From peptidoglycan to glycoproteins: common features of lipid-linked oligosaccharide biosynthesis. FEMS Microbiol Lett. 1994;119(3):255–262. doi:10.1111/j.1574-6968.1994.tb06898.x8050708
   PubMed Web of Science ®Google Scholar
• de Leeuw E, Li C, Zeng P, et al. Functional interaction of human neutrophil peptide-1 with the cell wall precursor lipid II. FEBS Lett. 2010;584(8):1543–1548. doi:10.1016/j.febslet.2010.03.00420214904
   PubMed Web of Science ®Google Scholar
• Schmitt P, Wilmes M, Pugniere M, et al. Insight into invertebrate defensin mechanism of action: oyster defensins inhibit peptidoglycan biosynthesis by binding to lipid II. J Biol Chem. 2010;285(38):29208–29216. doi:10.1074/jbc.M110.14338820605792
   PubMed Web of Science ®Google Scholar
• Schneider T, Kruse T, Wimmer R, et al. Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science. 2010;328(5982):1168–1172. doi:10.1126/science.118572320508130
   PubMed Web of Science ®Google Scholar
• Knox JR, Pratt RF. Different modes of vancomycin and D-alanyl-D-alanine peptidase binding to cell wall peptide and a possible role for the vancomycin resistance protein. Antimicrob Agents Chemother. 1990;34(7):1342–1347. doi:10.1128/aac.34.7.13422386365
   PubMed Web of Science ®Google Scholar
• Somma S, Gastaldo L, Corti A. Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp. Antimicrob Agents Chemother. 1984;26(6):917–923. doi:10.1128/aac.26.6.9176240963
   PubMed Web of Science ®Google Scholar
• King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother. 2004;53(5):797–803. doi:10.1093/jac/dkh15615028667
   PubMed Web of Science ®Google Scholar
• Woodford N. Novel agents for the treatment of resistant Gram-positive infections. Expert Opin Investig Drugs. 2003;12(2):117–137. doi:10.1517/13543784.12.2.117
   PubMed Web of Science ®Google Scholar
• Schwalbe RS, McIntosh AC, Qaiyumi S, et al. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob Agents Chemother. 1996;40(10):2416–2419.8891155
   PubMed Web of Science ®Google Scholar
• Munch D, Engels I, Muller A, et al. Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin. Antimicrob Agents Chemother. 2015;59(2):772–781. doi:10.1128/AAC.02663-1425403671
   PubMed Web of Science ®Google Scholar
• Singh MP, Petersen PJ, Weiss WJ, et al. Mannopeptimycins, new cyclic glycopeptide antibiotics produced by Streptomyces hygroscopicus LL-AC98: antibacterial and mechanistic activities. Antimicrob Agents Chemother. 2003;47(1):62–69. doi:10.1128/aac.47.1.62-69.200312499170
   PubMed Web of Science ®Google Scholar
• Lee W, Schaefer K, Qiao Y, et al. The Mechanism of Action of Lysobactin. J Am Chem Soc. 2016;138(1):100–103. doi:10.1021/jacs.5b1180726683668
   PubMed Web of Science ®Google Scholar
• O’Connor RD, Singh M, Chang J, et al. Dual Mode of Action for Plusbacin A3 in Staphylococcus aureus. J Phys Chem B. 2017;121(7):1499–1505. doi:10.1021/acs.jpcb.6b1103928135800
   PubMed Web of Science ®Google Scholar
• Reynolds PE, Somner EA. Comparison of the target sites and mechanisms of action of glycopeptide and lipoglycodepsipeptide antibiotics. Drugs Exp Clin Res. 1990;16(8):385–389.2151441
   PubMedGoogle Scholar
• Stone KJ, Strominger JL. Mechanism of action of bacitracin: complexation with metal ion and C 55 -isoprenyl pyrophosphate. Proc Natl Acad Sci U S A. 1971;68(12):3223–3227. doi:10.1073/pnas.68.12.32234332017
   PubMed Web of Science ®Google Scholar
• Vertesy L, Ehlers E, Kogler H, et al. Friulimicins: novel lipopeptide antibiotics with peptidoglycan synthesis inhibiting activity from Actinoplanes friuliensis sp. nov. II. Isolation and structural characterization. J Antibiot (Tokyo). 2000;53(8):816–827. doi:10.7164/antibiotics.53.81611079804
   PubMed Web of Science ®Google Scholar
• Zong Y, Sun X, Gao H, et al. Developing Equipotent Teixobactin Analogues against Drug-Resistant Bacteria and Discovering a Hydrophobic Interaction between Lipid II and Teixobactin. J Med Chem. 2018;61(8):3409–3421. doi:10.1021/acs.jmedchem.7b0124129629769
   PubMed Web of Science ®Google Scholar
• Breukink E, Wiedemann I, van Kraaij C, et al. Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science. 1999;286(5448):2361–2364. doi:10.1126/science.286.5448.236110600751
   PubMed Web of Science ®Google Scholar
• Nakano MM, Zuber P. Molecular biology of antibiotic production in Bacillus. Crit Rev Biotechnol. 1990;10(3):223–240. doi:10.3109/073885590090382091702690
   PubMed Web of Science ®Google Scholar
• Schnell N, Entian KD, Schneider U, et al. Prepeptide sequence of epidermin, a ribosomally synthesized antibiotic with four sulphide-rings. Nature. 1988;333(6170):276–278. doi:10.1038/333276a02835685
   PubMed Web of Science ®Google Scholar
• Smith L, Hasper H, Breukink E, et al. Elucidation of the antimicrobial mechanism of mutacin 1140. Biochemistry. 2008;47(10):3308–3314. doi:10.1021/bi701262z18266322
   PubMed Web of Science ®Google Scholar
• Sashihara T, Kimura H, Higuchi T, et al. A novel lantibiotic, nukacin ISK-1, of Staphylococcus warneri ISK-1: cloning of the structural gene and identification of the structure. Biosci Biotechnol Biochem. 2000;64(11):2420–2428. doi:10.1271/bbb.64.242011193411
   PubMed Web of Science ®Google Scholar
• Demel RA, Peelen T, Siezen RJ, De Kruijff B, Kuipers OP, Nisin Z. mutant nisin Z and lacticin 481 interactions with anionic lipids correlate with antimicrobial activity A monolayer study. Eur J Biochem. 1996;235(1–2):267–274. doi:10.1111/j.1432-1033.1996.00267.x8631341
   PubMedGoogle Scholar
• Brötz H, Bierbaum G, Markus A, Molitor E, Sahl HG. Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism? Antimicrob Agents Chemother. 1995;39(3):714–719. doi:10.1128/aac.39.3.7147793878
   PubMed Web of Science ®Google Scholar
• Bauer R, Dicks LM. Mode of action of lipid II-targeting lantibiotics. Int J Food Microbiol. 2005;101(2):201–216. doi:10.1016/j.ijfoodmicro.2004.11.00715862882
   PubMed Web of Science ®Google Scholar
• Montville TJ, Chen Y. Mechanistic action of pediocin and nisin: recent progress and unresolved questions. Appl Microbiol Biotechnol. 1998;50(5):511–519.9917136
   PubMed Web of Science ®Google Scholar
• Somma S, Merati W, Parenti F. Gardimycin, a new antibiotic inhibiting peptidoglycan synthesis. Antimicrob Agents Chemother. 1977;11(3):396–401. doi:10.1128/aac.11.3.396404960
   PubMed Web of Science ®Google Scholar
• Wiedemann I, Bottiger T, Bonelli RR, et al. The mode of action of the lantibiotic lacticin 3147–a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol Microbiol. 2006;61(2):285–296. doi:10.1111/j.1365-2958.2006.05223.x16771847
   PubMed Web of Science ®Google Scholar
• El Ghachi M, Bouhss A, Barreteau H, et al. Colicin M exerts its bacteriolytic effect via enzymatic degradation of undecaprenyl phosphate-linked peptidoglycan precursors. J Biol Chem. 2006;281(32):22761–22772. doi:10.1074/jbc.M60283420016777846
   PubMed Web of Science ®Google Scholar
• Martinez B, Suarez JE, Rodriguez A. Lactococcin 972: a homodimeric lactococcal bacteriocin whose primary target is not the plasma membrane. Microbiology. 1996;142(Pt 9):2393–2398. doi:10.1099/00221287-142-9-239321818877
   PubMed Web of Science ®Google Scholar
• Varney KM, Bonvin AM, Pazgier M, et al. Turning defense into offense: defensin mimetics as novel antibiotics targeting lipid II. PLoS Pathog. 2013;9(11):e1003732. doi:10.1371/journal.ppat.100373224244161
   PubMed Web of Science ®Google Scholar
• Chauhan J, Cardinale S, Fang L, et al. Towards Development of Small Molecule Lipid II Inhibitors as Novel Antibiotics. PLoS One. 2016;11(10):e0164515. doi:10.1371/journal.pone.016451527776124
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010;70(7):859–886. doi:10.2165/11534440-000000000-0000020426497
   PubMed Web of Science ®Google Scholar
• Cornaglia G, Rossolini GM. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens. Clin Microbiol Infect. 2009;15(3):218–223. doi:10.1111/j.1469-0691.2009.02740.x
   Web of Science ®Google Scholar
• Stein GE, Wells EM. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Curr Med Res Opin. 2010;26(3):571–588. doi:10.1185/0300799090351205720055750
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29(11):1275–1279.19873687
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Trapp S, Gin AS, et al. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections. Expert Rev Anti Infect Ther. 2008;6(1):67–81. doi:10.1586/14787210.6.1.6718251665
   PubMed Web of Science ®Google Scholar
• Cavalcanti AB, Goncalves AR, Almeida CS, Bugano DD, Silva E. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev. 20106:CD007022.
   PubMed Web of Science ®Google Scholar
• Schneider T, Sahl HG. An oldie but a goodie - cell wall biosynthesis as antibiotic target pathway. Int J Med Microbiol. 2010;300(2–3):161–169. doi:10.1016/j.ijmm.2009.10.00520005776
   PubMed Web of Science ®Google Scholar
• Charneski L, Patel PN, Sym D. Telavancin: a novel lipoglycopeptide antibiotic. Ann Pharmacother. 2009;43(5):928–938. doi:10.1345/aph.1G41719401479
   PubMed Web of Science ®Google Scholar
• Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis. 2006;42(Suppl 1):S25–S34. doi:10.1086/49171116323116
   PubMed Web of Science ®Google Scholar
• Gould IM. Is vancomycin redundant for serious staphylococcal infection? Int J Antimicrob Agents. 2010;36(Suppl 2):S55–S57. doi:10.1016/j.ijantimicag.2010.11.00521129922
   PubMed Web of Science ®Google Scholar
• Hughes D. Exploiting genomics, genetics and chemistry to combat antibiotic resistance. Nat Rev Genet. 2003;4(6):432–441. doi:10.1038/nrg108412776213
   PubMed Web of Science ®Google Scholar
• Jovetic S, Zhu Y, Marcone GL, Marinelli F, Tramper J. beta-Lactam and glycopeptide antibiotics: first and last line of defense? Trends Biotechnol. 2010;28(12):596–604. doi:10.1016/j.tibtech.2010.09.00420970210
   PubMed Web of Science ®Google Scholar
• McGuinness WA, Malachowa N, DeLeo FR. Vancomycin Resistance in Staphylococcus aureus. Yale J Biol Med. 2017;90(2):269–281.28656013
   PubMed Web of Science ®Google Scholar
• Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol. 2012;10(4):266–278. doi:10.1038/nrmicro276122421879
   PubMed Web of Science ®Google Scholar
• Whitener CJ, Park SY, Browne FA, et al. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin Infect Dis. 2004;38(8):1049–1055. doi:10.1086/38235715095205
   PubMed Web of Science ®Google Scholar
• Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003;348(14):1342–1347. doi:10.1056/NEJMoa02502512672861
   PubMed Web of Science ®Google Scholar
• Kim A, Kuti JL, Nicolau DP. Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Expert Opin Investig Drugs. 2007;16(5):717–733. doi:10.1517/13543784.16.5.717
   PubMed Web of Science ®Google Scholar
• Patti GJ, Kim SJ, Yu TY, et al. Vancomycin and oritavancin have different modes of action in Enterococcus faecium. J Mol Biol. 2009;392(5):1178–1191. doi:10.1016/j.jmb.2009.06.06419576226
   PubMed Web of Science ®Google Scholar
• Arthur M, Depardieu F, Reynolds P, Courvalin P. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci. Antimicrob Agents Chemother. 1999;43(8):1875–1880.10428906
   PubMed Web of Science ®Google Scholar
• Van Bambeke F. Lipoglycopeptide antibacterial agents in gram-positive infections: a comparative review. Drugs. 2015;75(18):2073–2095. doi:10.1007/s40265-015-0505-826603874
   PubMed Web of Science ®Google Scholar
• Klinker KP, Borgert SJ. Beyond Vancomycin: The Tail of the Lipoglycopeptides. Clin Ther. 2015;37(12):2619–2636. doi:10.1016/j.clinthera.2015.11.00726658277
   PubMed Web of Science ®Google Scholar
• Guskey MT, Tsuji BT. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy. 2010;30(1):80–94. doi:10.1592/phco.30.1.8020030476
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, O’Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis. 2005;40(11):1601–1607. doi:10.1086/42991415889357
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Chu VH, O’Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006;50(3):862–867. doi:10.1128/AAC.50.3.862-867.200616495243
   PubMed Web of Science ®Google Scholar
• Leonard SN, Szeto YG, Zolotarev M, Grigoryan IV. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA). Int J Antimicrob Agents. 2011;37(6):558–561. doi:10.1016/j.ijantimicag.2011.02.00721497067
   PubMed Web of Science ®Google Scholar
• Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2006;58(2):338–343. doi:10.1093/jac/dkl23516787952
   PubMed Web of Science ®Google Scholar
• Laohavaleeson S, Kuti JL, Nicolau DP. Telavancin: a novel lipoglycopeptide for serious gram-positive infections. Expert Opin Investig Drugs. 2007;16(3):347–357. doi:10.1517/13543784.16.3.347
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008;46(11):1683–1693. doi:10.1086/58789618444791
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis. 2011;52(1):31–40. doi:10.1093/cid/ciq03121148517
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Lentnek A, O’Riordan W, et al. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis. 2014;14:289. doi:10.1186/1471-2334-14-28924884578
   PubMed Web of Science ®Google Scholar
• Polyzos KA, Mavros MN, Vardakas KZ, et al. Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. PLoS One. 2012;7(8):e41870. doi:10.1371/journal.pone.004187022916113
   PubMed Web of Science ®Google Scholar
• Torres A, Rubinstein E, Corey GR, Stryjewski ME, Barriere SL. Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure. J Antimicrob Chemother. 2014;69(4):1119–1126. doi:10.1093/jac/dkt49024398339
   PubMed Web of Science ®Google Scholar
• Bosso JA, Nappi J, Rudisill C, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother. 2011;55(12):5475–5479. doi:10.1128/AAC.00168-1121947388
   PubMed Web of Science ®Google Scholar
• Dunbar LM, Milata J, McClure T, Wasilewski MM, Team SS. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother. 2011;55(7):3476–3484. doi:10.1128/AAC.00029-1121537018
   PubMed Web of Science ®Google Scholar
• Corey GR, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370(23):2180–2190. doi:10.1056/NEJMoa131042224897083
   PubMed Web of Science ®Google Scholar
• Corey GR, Good S, Jiang H, et al. Single-dose oritavancin versus 7–10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60(2):254–262. doi:10.1093/cid/ciu77825294250
   PubMed Web of Science ®Google Scholar
• Corey GR, Arhin FF, Wikler MA, et al. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2016;48(5):528–534. doi:10.1016/j.ijantimicag.2016.07.01927665522
   PubMed Web of Science ®Google Scholar
• Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003;37(10):1298–1303. doi:10.1086/37901514583862
   PubMed Web of Science ®Google Scholar
• Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169–2179. doi:10.1056/NEJMoa131048024897082
   PubMed Web of Science ®Google Scholar
• Dunne MW, Puttagunta S, Giordano P, et al. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection. Clin Infect Dis. 2016;62(5):545–551. doi:10.1093/cid/civ98226611777
   PubMed Web of Science ®Google Scholar
• Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005;40(3):374–380. doi:10.1086/42728315668859
   PubMed Web of Science ®Google Scholar
• Dunne MW, Puttagunta S, Sprenger CR, et al. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59(4):1849–1855. doi:10.1128/AAC.04550-1425561338
   PubMed Web of Science ®Google Scholar
• de la Cruz M, Gonzalez I, Parish CA, et al. Production of Ramoplanin and Ramoplanin Analogs by Actinomycetes. Front Microbiol. 2017;8:343. doi:10.3389/fmicb.2017.0034328321210
   PubMed Web of Science ®Google Scholar
• Hamburger JB, Hoertz AJ, Lee A, et al. A crystal structure of a dimer of the antibiotic ramoplanin illustrates membrane positioning and a potential Lipid II docking interface. Proc Natl Acad Sci U S A. 2009;106(33):13759–13764. doi:10.1073/pnas.090468610619666597
   PubMed Web of Science ®Google Scholar
• Cheng M, Huang JX, Ramu S, Butler MS, Cooper MA. Ramoplanin at bactericidal concentrations induces bacterial membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. 2014;58(11):6819–6827. doi:10.1128/AAC.00061-1425182650
   PubMed Web of Science ®Google Scholar
• Montecalvo MA. Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J Antimicrob Chemother. 2003;51(Suppl 3):iii31–iii35. doi:10.1093/jac/dkg27412801940
   PubMed Web of Science ®Google Scholar
• Wong MT, Kauffman CA, Standiford HC, et al. Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis. 2001;33(9):1476–1482. doi:10.1086/32268711588692
   PubMed Web of Science ®Google Scholar
• Bonner DP, O’Sullivan J, Tanaka SK, Clark JM, Whitney RR. Lysobactin, a novel antibacterial agent produced by Lysobacter sp. II. Biological properties. J Antibiot (Tokyo). 1988;41(12):1745–1751. doi:10.7164/antibiotics.41.17453209466
   PubMed Web of Science ®Google Scholar
• Economou NJ, Cocklin S, Loll PJ. High-resolution crystal structure reveals molecular details of target recognition by bacitracin. Proc Natl Acad Sci U S A. 2013;110(35):14207–14212. doi:10.1073/pnas.130826811023940351
   PubMed Web of Science ®Google Scholar
• Kim SJ, Singh M, Wohlrab A, et al. The isotridecanyl side chain of plusbacin-A3 is essential for the transglycosylase inhibition of peptidoglycan biosynthesis. Biochemistry. 2013;52(11):1973–1979. doi:10.1021/bi400022223421534
   PubMed Web of Science ®Google Scholar
• Schneider T, Gries K, Josten M, et al. The lipopeptide antibiotic Friulimicin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate. Antimicrob Agents Chemother. 2009;53(4):1610–1618. doi:10.1128/AAC.01040-0819164139
   PubMed Web of Science ®Google Scholar
• Ling LL, Schneider T, Peoples AJ, et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015;517(7535):455–459. doi:10.1038/nature1409825561178
   PubMed Web of Science ®Google Scholar
• Smith L, Hillman J. Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics. Curr Opin Microbiol. 2008;11(5):401–408. doi:10.1016/j.mib.2008.09.00818848642
   PubMed Web of Science ®Google Scholar
• Rogers LA, Whittier EO. Limiting Factors in the Lactic Fermentation. J Bacteriol. 1928;16(4):211–229.16559334
   PubMedGoogle Scholar
• Delves-Broughton J, Blackburn P, Evans RJ, Hugenholtz J. Applications of the bacteriocin, nisin. Antonie Van Leeuwenhoek. 1996;69(2):193–202.8775979
   PubMed Web of Science ®Google Scholar
• Cotter PD, Hill C, Ross RP. Bacteriocins: developing innate immunity for food. Nat Rev Microbiol. 2005;3(10):777–788. doi:10.1038/nrmicro127316205711
   PubMed Web of Science ®Google Scholar
• Karakas Sen A, Narbad A, Horn N, et al. Post-translational modification of nisin. The involvement of NisB in the dehydration process. Eur J Biochem. 1999;261(2):524–532. doi:10.1046/j.1432-1327.1999.00303.x10215865
   PubMedGoogle Scholar
• Wiedemann I, Breukink E, van Kraaij C, et al. Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J Biol Chem. 2001;276(3):1772–1779. doi:10.1074/jbc.M00677020011038353
   PubMed Web of Science ®Google Scholar
• Medeiros-Silva J, Jekhmane S, Paioni AL, et al. High-resolution NMR studies of antibiotics in cellular membranes. Nat Commun. 2018;9(1):3963. doi:10.1038/s41467-018-06314-x30262913
   PubMed Web of Science ®Google Scholar
• Medeiros-Silva J, Jekhmane S, Breukink E, Weingarth M. Towards the native binding modes of Lipid II targeting antibiotics. Chembiochem. 2019. doi:10.1002/cbic.201800796
   Web of Science ®Google Scholar
• Scherer KM, Spille JH, Sahl HG, Grein F, Kubitscheck U. The lantibiotic nisin induces lipid II aggregation, causing membrane instability and vesicle budding. Biophys J. 2015;108(5):1114–1124. doi:10.1016/j.bpj.2015.01.02025762323
   PubMed Web of Science ®Google Scholar
• Oppedijk SF, Martin NI, Breukink E. Hit ‘em where it hurts: the growing and structurally diverse family of peptides that target lipid-II. Biochim Biophys Acta. 2016;1858(5):947–957. doi:10.1016/j.bbamem.2015.10.02426523408
   PubMed Web of Science ®Google Scholar
• Kramer NE, Smid EJ, Kok J, et al. Resistance of Gram-positive bacteria to nisin is not determined by lipid II levels. FEMS Microbiol Lett. 2004;239(1):157–161. doi:10.1016/j.femsle.2004.08.03315451114
   PubMed Web of Science ®Google Scholar
• Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005;3(3):238–250. doi:10.1038/nrmicro109815703760
   PubMed Web of Science ®Google Scholar
• Lehrer RI, Barton A, Daher KA, et al. Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J Clin Invest. 1989;84(2):553–561. doi:10.1172/JCI1141982668334
   PubMed Web of Science ®Google Scholar
• Hadjicharalambous C, Sheynis T, Jelinek R, et al. Mechanisms of alpha-defensin bactericidal action: comparative membrane disruption by Cryptdin-4 and its disulfide-null analogue. Biochemistry. 2008;47(47):12626–12634. doi:10.1021/bi800335e18973303
   PubMed Web of Science ®Google Scholar
• de Leeuw E, Burks SR, Li X, Kao JP, Lu W. Structure-dependent functional properties of human defensin 5. FEBS Lett. 2007;581(3):515–520. doi:10.1016/j.febslet.2006.12.03617250830
   PubMed Web of Science ®Google Scholar
• Ericksen B, Wu Z, Lu W, Lehrer RI. Antibacterial activity and specificity of the six human {alpha}-defensins. Antimicrob Agents Chemother. 2005;49(1):269–275. doi:10.1128/AAC.49.1.269-275.200515616305
   PubMed Web of Science ®Google Scholar
• Zou G, de Leeuw E, Li C, et al. Toward understanding the cationicity of defensins: ARG and LYS versus their noncoded analogs. J Biol Chem. 2007. doi:10.1074/jbc.M611003200.
   Web of Science ®Google Scholar
• Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003;3(9):710–720. doi:10.1038/nri118012949495
   PubMed Web of Science ®Google Scholar
• Sass V, Schneider T, Wilmes M, et al. Human beta-defensin 3 inhibits cell wall biosynthesis in Staphylococci. Infect Immun. 2010;78(6):2793–2800. doi:10.1128/IAI.00688-0920385753
   PubMed Web of Science ®Google Scholar
• Maisetta G, Batoni G, Esin S, et al. Activity of human beta-defensin 3 alone or combined with other antimicrobial agents against oral bacteria. Antimicrob Agents Chemother. 2003;47(10):3349–3351. doi:10.1128/aac.47.10.3349-3351.200314506056
   PubMed Web of Science ®Google Scholar
• Pazger M, Wei G, Ericksen B, et al. Sometimes It Takes Two to Tango: Contributions of dimerization to functions of human alpha-defensin HNP1 Peptide. J Biol Chem. 2012;287(12):8944–8953. doi:10.1074/jbc.M111.33220522270360
   PubMed Web of Science ®Google Scholar
• Pazgiera M, Hoover DM, Yang D, Lu W, Lubkowski J. Human beta-defensins. Cell Mol Life Sci. 2006;63(11):1294–1313. doi:10.1007/s00018-005-5540-216710608
   PubMed Web of Science ®Google Scholar
• Wei G, de Leeuw E, Pazgier M, et al. Through the looking glass, mechanistic insights from enantiomeric human defensins. J Biol Chem. 2009;284(42):29180–29192. doi:10.1074/jbc.M109.01808519640840
   PubMed Web of Science ®Google Scholar
• Yang D, Biragyn A, Hoover DM, Lubkowski J, Oppenheim JJ. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol. 2004;22:181–215. doi:10.1146/annurev.immunol.22.012703.10460315032578
   PubMed Web of Science ®Google Scholar
• Andes D, Craig W, Nielsen LA, Kristensen HH. In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection model. Antimicrob Agents Chemother. 2009;53(7):3003–3009. doi:10.1128/AAC.01584-0819414576
   PubMed Web of Science ®Google Scholar
• Jiao J, Mao R, Teng D, et al. In vitro and in vivo antibacterial effect of NZ2114 against Streptococcus suis type 2 infection in mice peritonitis models. AMB Express. 2017;7(1):44. doi:10.1186/s13568-017-0347-828220445
   PubMed Web of Science ®Google Scholar
• Klein K, Gronnemose RB, Alm M, et al. Controlled Release of Plectasin NZ2114 from a Hybrid Silicone-Hydrogel Material for Inhibition of Staphylococcus aureus Biofilm. Antimicrob Agents Chemother. 2017;61(7). doi:10.1128/AAC.00604-17.
   Web of Science ®Google Scholar
• de Leeuw EP. Efficacy of the small molecule inhibitor of Lipid II BAS00127538 against acinetobacter baumannii. Drug Des Devel Ther. 2014;8:1061–1064. doi:10.2147/DDDT.S68020
   PubMed Web of Science ®Google Scholar
• Fletcher S, Yu W, Huang J, et al. Structure-activity exploration of a small-molecule Lipid II inhibitor. Drug Des Devel Ther. 2015;9:2383–2394. doi:10.2147/DDDT.S79504
   Web of Science ®Google Scholar
• Srinivasan A, Dick JD, Perl TM. Vancomycin resistance in staphylococci. Clin Microbiol Rev. 2002;15(3):430–438. doi:10.1128/cmr.15.3.430-438.200212097250
   PubMed Web of Science ®Google Scholar
• O’Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist. 2015;8:217–230. doi:10.2147/IDR.S5412526244026
   PubMed Web of Science ®Google Scholar
• Bender JK, Fleige C, Klare I, et al. Detection of a cfr(B) variant in German Enterococcus faecium clinical isolates and the impact on linezolid resistance in enterococcus spp. PLoS One. 2016;11(11):e0167042. doi:10.1371/journal.pone.016704227893790
   PubMed Web of Science ®Google Scholar
• Fiedler S, Bender JK, Klare I, et al. Tigecycline resistance in clinical isolates of Enterococcus faecium is mediated by an upregulation of plasmid-encoded tetracycline determinants tet(L) and tet(M). J Antimicrob Chemother. 2016;71(4):871–881. doi:10.1093/jac/dkv42026682961
   PubMed Web of Science ®Google Scholar
• Derouaux A, Turk S, Olrichs NK, et al. Small molecule inhibitors of peptidoglycan synthesis targeting the lipid II precursor. Biochem Pharmacol. 2011;81(9):1098–1105. doi:10.1016/j.bcp.2011.02.00821356201
   PubMed Web of Science ®Google Scholar